Chemotherapy in Osteosarcoma

Kapadia, Asha; Sachin, Almel; Muzammil, Shaikh

doi:10.5772/45726

Cited by 3 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the time of surgery, approximately 40-70% of patients have a poor histologic response (Hauben et al, 2002;Asha et al, 2012). For patients with a poor response, salvage therapy modifies the post-surgery chemotherapy regimen in hopes of better patient outcomes.…”

Section: Prognostic Markersmentioning

confidence: 99%

“…Since an initial success in the 1980's (Rosen et al, 1979), salvage therapy has been unsuccessful at improving the outcome of poor responders (Meyers et al, 1992;Carrle and Bielack, 2006;Provisor et al, 1997;Winkler et al, 1988; The ESMO/European Sarcoma Network Working Group, 2014). The delayed evaluation of treatment response could be a reason for continued poor outcomes (Asha et al, 2012), emphasizing the need to identify poor responders early in treatment before surgery.…”

Section: Prognostic Markersmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Feasibility of Diffuse Optical Spectroscopic Imaging for Sarcoma

Peterson

2016

Biomedical Optics 2016

View full text Add to dashboard Cite

I have the best family and friends. You have created a support network that has allowed me to grow and overcome. I could not have done this without you. Darren, thank you for being my advisor. You have given me freedom to explore and discover. Bang, thank you for being my co-sponsor. You have coached me in the clinic and encouraged me with your unwavering enthusiasm for me and this project. I am grateful to my committee members, Cathie, Elise, and Ji, for guiding this project and me. I would like to acknowledge all members of the BOTLab, past and present, for their friendship and support, especially my fellow DOSI collaborators. Brannon, thank you for curiosity and patience while creating the phantom set. Professor Bigio, from my first year as an academic advisee to my final year as a Ph.D., you have been a steadfast mentor and an example of a student ally and advocate. I had a lot of help from my clinical collaborators. At Montefiore Medical Center and MD Anderson Cancer Center, I would like to acknowledge Drs. Bang Hoang, David Geller, Rui Yang, and Richard Gorlick. Thank you so much for your enthusiasm and support, you have been amazing collaborators. I also want to acknowledge Janet, Jeremy, and Damian, for coordinating measurements, consenting subjects, extracting patient data, documenting IRB amendments, and guiding me and this project. At Boston Medical Center, I would like to thank Liz, Salli, Jill, Meredith, Jen, Joanna, Malti, Debbie, and Nancy for all their help. Liz, I'll miss doing the DOSI-DO with you. For when everything falls apart, thank you Chris, Dan, and Eric at the Electronic Design Facility for helping me put it back together again. From measurements to data processing to repairs, I would also like to thank Anais, Amanda, and Tom for imparting all of their DOSI knowledge and wisdom. Within the Biomedical Engineerv ing Department, I'm so grateful for all the help, support, and laughs from Christen, Will, Allie, Stephanie, Nicole, and Tara.

show abstract

Section: Prognostic Markersmentioning

confidence: 99%

Section: Prognostic Markersmentioning

confidence: 99%

Clinical Feasibility of Diffuse Optical Spectroscopic Imaging for Sarcoma

Peterson

2016

Biomedical Optics 2016

View full text Add to dashboard Cite

show abstract

“…Additionaly, this biomarker can only be determined at the time of surgery, weeks or months after the start of intensive chemotherapy. [15][16][17] The inability to adequately evaluate treatment response may contribute to continued poor outcomes, 18 emphasizing the need to identify poor responders early in treatment before surgery.…”

Section: Introductionmentioning

confidence: 99%

In vivo, noninvasive functional measurements of bone sarcoma using diffuse optical spectroscopic imaging

et al. 2017

View full text Add to dashboard Cite

Diffuse optical spectroscopic imaging (DOSI) is an emerging near-infrared imaging technique that noninvasively measures quantitative functional information in thick tissue. This study aimed to assess the feasibility of using DOSI to measure optical contrast from bone sarcomas. These tumors are rare and pose technical and practical challenges for DOSI measurements due to the varied anatomic locations and tissue depths of presentation. Six subjects were enrolled in the study. One subject was unable to be measured due to tissue contact sensitivity. For the five remaining subjects, the signal-to-noise ratio, imaging depth, optical properties, and quantitative tissue concentrations of oxyhemoglobin, deoxyhemoglobin, water, and lipids from tumor and contralateral normal tissues were assessed. Statistical differences between tumor and contralateral normal tissue were found in chromophore concentrations and optical properties for four subjects. Low signal-to-noise was encountered during several subject's measurements, suggesting increased detector sensitivity will help to optimize DOSI for this patient population going forward. This study demonstrates that DOSI is capable of measuring optical properties and obtaining functional information in bone sarcomas. In the future, DOSI may provide a means to stratify treatment groups and monitor chemotherapy response for this disease.

show abstract